期刊文献+

Box-Behnken效应面法优化多西他赛微乳注射液制备工艺 被引量:5

Optimization of the Preparation Technology of Docetaxel Microemulsion Injection by Box-Behnken Design and Response Surface Method
原文传递
导出
摘要 目的:优化微乳制备工艺,制备多西他赛微乳注射液。方法:采用高压均质法制备多西他赛微乳,以制备温度、均质压力和均质次数为考察对象,以粒径分布、多分散系数和包封率为评价指标,采用Box-Behnken效应面法优化多西他赛微乳的制备工艺;采用Mastersizer粒度仪测定微乳的粒径分布,考察多分散系数及Zeta电位,透射电镜考察其形态。结果:多西他赛微乳优化工艺为制备温度61℃,均质压力860×105Pa,均质次数7次;所得微乳的粒径为(221.6±13.4)nm,多分散系数为0.092±0.003,Zeta电位为-30.3mV,包封率为(93.4±2.1)%;透射电镜显示微乳粒径均一,呈球状分布。结论:多西他赛微乳制备工艺采用Box-Behnken效应面法优化是有效、可行的。 OBJECTIVE:To optimize the preparation technology of microemulsion,and to prepare Docetaxel microemulsion injection.METHODS:Docetaxel microemulsion was prepared using high pressure homogenization.The preparation technology of Docetaxel microemulsion was optimized by Box-Behnken design and response surface method with preparation temperature,homogenization pressure and homogenization times as factors using particle size distribution,polydispersity index and entrapment efficiency as index.The distribution of particle size,polydispersion index and Zeta potential were determined by Mastersizer particle analyzer;the morphology of Docetaxel microemulsion was observed under TEM.RESULTS:Optimized preparation technology was as follows:preparation temperature of 61 ℃,homogenization pressure of 860×10 5 Pa,homogenization times of 7.The microemulsions were characterized with particle size of(221.6±13.4)nm,polydispersion index of(0.092±0.003),Zeta potential of-30.3 mV,encapsulation efficiency of(93.4 ± 2.1)%.The microemulsions were found to be homogeneous and spherical under TEM.CONCLUSIONS:It is effective and practical that Box-Behnken design and response method optimizes the preparation technology of Docetaxel microemulsion.
出处 《中国药房》 CAS CSCD 2013年第29期2742-2745,共4页 China Pharmacy
关键词 多西他赛微乳注射液 制备 高压均质法 BOX-BEHNKEN效应面法 Docetaxel microemulsion injection Preparation High pressure homogenization Box-Behnken design and response method
  • 相关文献

参考文献9

  • 1ten Tije AJ, Verweij J, Loos WJ, et al. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy[J]. Clin Pharmacokinet, 2003,42 (7) : 665.
  • 2Straubinger RM, Balasubrltmanian SV. Preparation and characterization of taxane-containing liposomes[J]. Meth- ods Enzymol, 2005,391 (3) : 97.
  • 3张先林.抗肿瘤药多西紫杉醇制剂的应用研究近况[J].药学进展,2006,30(11):516-520. 被引量:26
  • 4刘沙,熊非,朱家壁,顾宁.静脉注射用载药脂肪乳的研究近况[J].药学进展,2010,34(3):104-109. 被引量:10
  • 5MacFie J. The development of fat emulsion[J]. Nutrition, 1999,15(7/8) :641.
  • 6Zhao M, Su M, Lin X, et al. Evaluation of docetaxel- loaded intravenous lipid emulsion pharmacokinetics, tis- sue distribution, antitumor activity, safety and toxicity [J]. Pharm Res, 2010,27(8) : 1 687.
  • 7Nielloud F, Marti-Mestres G. Pharmaceutical emulsions and suspensions[M]. New York: Marcel Dekker Inc, 2000: 214-2t5.
  • 8苏德森,王思玲.物理药剂学[M].北京:化学工业出版社,2003:144-146.
  • 9马涛.全合一混合液(All In One Admixture)的稳定性[J].中国药房,2000,11(2):88-90. 被引量:23

二级参考文献60

共引文献57

同被引文献28

引证文献5

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部